Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
Open-market buys, last 90 days
$949,381
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Ciongoli Gregory Austin +$949K Director 1 filing

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-04-18 Christmas Patrick J. SVP, General Counsel Exercise or conversion · Employee Stock Option (Right to Buy) −3,541 49,931
2019-04-18 Christmas Patrick J. SVP, General Counsel Exercise or conversion · Stock Option (Right to Buy) −1,459 9,641
2019-04-17 PAKOLA STEVE Chief Medical Officer Grant or award · Stock Option (Right to Buy) +95,000 95,000
2019-04-15 Danos Olivier Chief Scientific Officer Exercise or conversion +2,000 $20.35 $41K 8,500
2019-04-15 Danos Olivier Chief Scientific Officer Sale −1,000 $52.23 $52K 7,500
2019-04-15 Danos Olivier Chief Scientific Officer Sale −1,000 $53.09 $53K 6,500
2019-04-15 Danos Olivier Chief Scientific Officer Exercise or conversion · Stock Option (Right to Buy) −2,000 71,500
2019-03-21 Vasista Vittal Chief Financial Officer Sale −8,300 $60.64 $503K 230,915
2019-03-21 Vasista Vittal Chief Financial Officer Sale −1,700 $61.31 $104K 229,215
2019-03-19 Mills Kenneth T. President and CEO Exercise or conversion +15,000 $0.85 $13K 261,000
2019-03-19 Mills Kenneth T. President and CEO Sale −5,870 $58.21 $342K 255,130
2019-03-19 Mills Kenneth T. President and CEO Sale −9,130 $58.74 $536K 246,000
2019-03-19 Mills Kenneth T. President and CEO Exercise or conversion · Employee Stock Option (Right to Buy) −15,000 159,670
2019-03-12 Danos Olivier Chief Scientific Officer Exercise or conversion +5,000 $20.35 $102K 6,500
2019-03-12 Danos Olivier Chief Scientific Officer Exercise or conversion · Stock Option (Right to Buy) −5,000 73,500
2019-03-05 Vasista Vittal Chief Financial Officer Sale −3,068 $60.01 $184K 239,215
2019-02-25 Simpson Curran SVP, Product Development & CTO Exercise or conversion +5,300 $35.80 $190K 44,800
2019-02-25 Simpson Curran SVP, Product Development & CTO Sale −5,300 $54.05 $286K 39,500
2019-02-25 Simpson Curran SVP, Product Development & CTO Exercise or conversion · Stock Option (Right to Buy) −5,300 41,250
2019-02-15 Mills Kenneth T. President and CEO Sale −3,412 $45.96 $157K 257,588

Page 29 of 43 · 852 trades